FASN Antibody | 62-917

FASN Antibody | 62-917 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human

Homology: N/A

Immunogen: This FASN antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 942-973 amino acids from the Central region of human FASN.

Research Area: Cancer, Obesity, Neuroscience, Signal Transduction

Tested Application: WB, IHC-P, IF, Flow

Application: For WB starting dilution is: 1:16000
For IF starting dilution is: 1:200
For IHC-P starting dilution is: 1:10~50
For FACS starting dilution is: 1:10~50

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: 273 kDa

Validation: N/A

Isoform: N/A

Purification: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis

Clonality: Polyclonal

Clone: N/A

Isotype: Rabbit Ig

Conjugate: Unconjugated

Physical State: Liquid

Buffer: Supplied in PBS with 0.09% (W/V) sodium azide.

Concentration: batch dependent

Storage Condition: Store at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: Fatty acid synthase, [Acyl-carrier-protein] S-acetyltransferase, [Acyl-carrier-protein] S-malonyltransferase, 3-oxoacyl-[acyl-carrier-protein] synthase, 3-oxoacyl-[acyl-carrier-protein] reductase, 3-hydroxyacyl-[acyl-carrier-protein] dehydratase, Enoyl-[acyl-carrier-protein] reductase, Oleoyl-[acyl-carrier-protein] hydrolase, FASN, FAS

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: FASN is a multifunctional protein. Its main function is to catalyze the synthesis of palmitate from acetyl-CoA and malonyl-CoA, in the presence of NADPH, into long-chain saturated fatty acids. In some cancer cell lines, this protein has been found to be fused with estrogen receptor-alpha (ER-alpha) , in which the N-terminus of FAS is fused in-frame with the C-terminus of ER-alpha.